Table 3 Association of clinical, pathological and genomic characteristics with PFS and OS in the control group
| Characteristics |
N (107) | Progression Free Survival | Overall Survival | |||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | p | |||
| Sex | Females | 39 | 1 | 1 | ||||
| Males | 68 | 0.97 | 0.65-1.45 | 0.893 | 0.83 | 0.51-1.30 | 0.397 | |
| Age | ≤ 65 years | 60 | 1 | 1 | ||||
| >65 years | 47 | 0.78 | 0.51-1.15 | 0.197 | 0.94 | 0.61-1.44 | 0.782 | |
| ECOG PS | 0 | 83 | 1 | 1 | ||||
| 1-2 | 24 | 1.34 | 0.84-2.31 | 0.196 | 2.32 | 1.68-6.23 | 0.0004 | |
| Previous adjuvant CT | No | 75 | 1 | 1 | ||||
| Yes | 32 | 1.13 | 0.74-1.75 | 0.562 | 0.77 | 0.49-1.22 | 0.268 | |
| No. of metastatic sites | 1 | 57 | 1 | 1 | ||||
| >1 | 50 | 1.10 | 0.75-1.62 | 0.632 | 0.88 | 0.57-1.34 | 0.542 | |
| Liver-only metastases | No | 68 | 1 | 1 | ||||
| Yes | 39 | 0.81 | 0.54-1.19 | 0.270 | 0.97 | 0.63-1.51 | 0.901 | |
| High CEA level | No | 85 | 1 | 1 | ||||
| Yes | 22 | 1.45 | 0.91-2.68 | 0.109 | 1.91 | 1.22-4.36 | 0.010 | |
| -1498 | C/C | 25 | 1 | 1 | ||||
| C/T | 55 | 1.09 | 0.68-1.76 | 0.719 | 0.89 | 0.50-1.55 | 0.662 | |
| T/T | 27 | 0.89 | 0.50-1.54 | 0.653 | 0.73 | 0.36-1.39 | 0.311 | |
